EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients

Osamu Shiraishi, Hiroaki Kato, Kota Momose, Yoko Hiraki, Atsushi Yasuda, Masayuki Shinkai, Motohiro Imano, Takushi Yasuda

Oncology · 2023

DOI: 10.1159/000528937 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2023. Verfasst von Osamu Shiraishi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to clarify the impact of the average relative dose intensity (RDI) of neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-NAC) for resectable locally advanced esophageal squamous cell carcinoma (ESCC). Materials and Methods: To identify the optimal RDI, recurrence-free survival (RFS) and cumulative incidence function (CIF) for recurrence were calculated in low and high RDI groups with any cut-off points. The optimal RDI was defined as the highest RDI administered with a significant increase in either RFS or CIF. The clinicopathological characteristics of the two groups divided by optimal RDI were investigated. The preoperative prognostic factors associated with RFS were confirmed by multivariable Cox proportional hazards model.

Results

Among the 150 eligible patients treated with DCF-NAC from 2010 to 2020, 3-year RFS and CIF were 56.3% and 37.8% in 90 patients in the less than 80% RDI group (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaCarcinoma, Squamous CellEsophageal NeoplasmsHumansCisplatinDocetaxelFluorouracilNeoadjuvant TherapyTaxoidsAntineoplastic Combined Chemotherapy ProtocolsRetrospective Studies

Stichwörter der Autor:innen

Esophageal cancerNeoadjuvant chemotherapyRelative dose intensity

Substanzen

CisplatinDocetaxelFluorouracilTaxoids

Autor:innen und Institutionen

  • Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

Zitieren

APA

Shiraishi, O., Kato, H., Momose, K., Hiraki, Y., Yasuda, A., Shinkai, M., Imano, M., & Yasuda, T. (2023). Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients. Oncology. https://doi.org/10.1159/000528937

Vancouver

Shiraishi O, Kato H, Momose K, Hiraki Y, Yasuda A, Shinkai M, et al. Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients. Oncology. 2023. doi:10.1159/000528937

BibTeX
@article{Shiraishi2023,
  author = {Shiraishi, Osamu and Kato, Hiroaki and Momose, Kota and Hiraki, Yoko and Yasuda, Atsushi and Shinkai, Masayuki and Imano, Motohiro and Yasuda, Takushi},
  title = {Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients},
  journal = {Oncology},
  year = {2023},
  doi = {10.1159/000528937}
}
Kostenlos starten →